Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency Journal Article


Authors: Shia, J.; Zhang, L.; Shike, M.; Guo, M.; Stadler, Z.; Xiong, X.; Tang, L. H.; Vakiani, E.; Katabi, N.; Wang, H.; Bacares, R.; Ruggeri, J.; Boland, C. R.; Ladanyi, M.; Klimstra, D. S.
Article Title: Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
Abstract: Immunohistochemical staining for DNA mismatch repair proteins may be affected by various biological and technical factors. Staining variations that could potentially lead to erroneous interpretations have been recognized. A recently recognized staining variation is the significant reduction of staining for MSH6 in some colorectal carcinomas. The frequency and specific characteristics of this aberrant MSH6 staining pattern, however, have not been well analyzed. In this study of 420 colorectal carcinoma samples obtained from patients fulfilling the Revised Bethesda Guidelines, we detected 9 tumors (2%) showing extremely limited staining for MSH6 with positive staining present in <5% of the tumor cells. Our analyses showed that these tumors belonged to two distinct categories: (1) MLH1 and/or PMS2 protein-deficient carcinomas (n=5, including 1 with a pathogenic mutation in PMS2); and (2) MLH1, PMS2 and MSH2 normal but with chemotherapy or chemoradiation therapy before surgery (n=4). To test our hypothesis that somatic mutation in the coding region microsatellite of the MSH6 gene might be a potential underlying mechanism for such limited MSH6 staining, we evaluated frameshift mutation in a (C) 8 tract in exon 5 of the MSH6 gene in seven tumors that had sufficient DNA for analysis, and detected mutation in four; all four tumors belonged to the MLH1/PMS2-deficient group. In conclusion, our data outline the main scenarios where significant reduction of MSH6 staining is more likely to occur in colorectal carcinoma, and suggest that somatic mutations of the coding region microsatellites of the MSH6 gene is an underlying mechanism for this staining phenomenon in MLH1/PMS2-deficient carcinomas. © 2013 USCAP, Inc.
Keywords: immunohistochemistry; adult; cancer chemotherapy; controlled study; protein expression; aged; gene mutation; major clinical study; exon; frameshift mutation; cancer patient; cancer diagnosis; practice guideline; microsatellite dna; colorectal carcinoma; dna; microsatellite instability; dna mismatch repair; staining; clinical evaluation; tumor cell; protein deficiency; genetic code; protein mlh1; lynch syndrome; protein msh6; dna determination; mismatch repair protein pms2; chemoradiotherapy; base mispairing; hereditary non-polyposis colorectal carcinoma
Journal Title: Modern Pathology
Volume: 26
Issue: 1
ISSN: 0893-3952
Publisher: Nature Research  
Date Published: 2013-01-01
Start Page: 131
End Page: 138
Language: English
DOI: 10.1038/modpathol.2012.138
PROVIDER: scopus
PUBMED: 22918162
PMCID: PMC3793326
DOI/URL:
Notes: --- - "Export Date: 1 February 2013" - "CODEN: MODPE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Moshe Shike
    168 Shike
  2. Hangjun Wang
    12 Wang
  3. Liying Zhang
    129 Zhang
  4. Zsofia Kinga Stadler
    389 Stadler
  5. Nora Katabi
    303 Katabi
  6. David S Klimstra
    978 Klimstra
  7. Marc Ladanyi
    1326 Ladanyi
  8. Jinru Shia
    717 Shia
  9. Laura Hong Tang
    447 Tang
  10. Xiaoling Xiong
    6 Xiong
  11. Efsevia Vakiani
    263 Vakiani
  12. Ruben Bacares
    18 Bacares
  13. Min Guo
    11 Guo